Cytogen Corporation
650 College Road East
Princeton
New Jersey
08540
United States
Tel: 609-750-8200
Fax: 609-452-2476
Website: http://www.cytogen.com/
About Cytogen Corporation
Cytogen Corporation is a biopharmaceutical company with an established and growing product line in prostate cancer and other areas of oncology. Currently marketed products include ProstaScintâ (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeedä I-125 and Pd-103 (two uniquely designed next generation radioactive seed implants for the treatment of localized prostate cancer), and Quadrametâ (a skeletal targeting therapeutic radiopharmaceutical marketed for the relief of bone pain in prostate and other types of cancer). Cytogen is evolving a pipeline of oncology product candidates by developing its prostate specific membrane antigen, or PSMA, technologies, which are exclusively licensed from Memorial Sloan-Kettering Cancer Center. AxCell Biosciences of Newtown, PA, a subsidiary of Cytogen Corporation, is engaged in the research and development of novel biopharmaceutical products using its portfolio of functional proteomics solutions and collection of proprietary signal transduction pathway information.Last Updated: 10-16-02
100 articles about Cytogen Corporation
-
EUSA Pharma Completes Acquisition Of Cytogen Corporation
5/9/2008
-
Cytogen Corporation Reports First Quarter 2008 Financial Results
5/8/2008
-
Cytogen Corporation's Auditors Expressed Going-Concern Qualification
3/20/2008
-
Cytogen Corporation Reports Fourth Quarter and Full Year 2007 Financial Results
3/14/2008
-
Cytogen Corporation Says CEO Resigns; Names Replacement
11/12/2007
-
Cytogen Corporation Retains ThinkEquity Partners to Assist in the Evaluation of Potential Strategic Alternatives
11/5/2007
-
Cytogen Corporation Reports Third Quarter 2007 Financial Results
11/5/2007
-
Cytogen Corporation to Present at the Biotechnology Industry Organization (BIO) Investor Forum 2007
10/3/2007
-
Outcomes Data Demonstrating Prognostic Value of Cytogen Corporation's PROSTASCINT Published in Peer-Reviewed Journal Urology
9/10/2007
-
Cytogen Corporation to Present at Upcoming Investor Conferences in September
8/28/2007
-
Cytogen Corporation to Raise $10.1 Million through Private Placement of Common Stock and Warrants
7/2/2007
-
Cytogen Corporation Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of QUADRAMET(R) at International Myeloma Workshop
6/28/2007
-
Cytogen Corporation Announces New Sales and Marketing Leadership with the Appointment of Stephen A. Ross
6/11/2007
-
New Data for Cytogen Corporation's QUADRAMET(R) Reported at Annual American Society of Clinical Oncology Meeting
6/4/2007
-
Cytogen Corporation Reports Publication Validating the Utility of its Proprietary ProChart(TM) Database
5/23/2007
-
Outcomes Data Continue to Demonstrate Value of Cytogen Corporation's PROSTASCINT(R) to Predict Prognosis in Prostate Cancer
5/22/2007
-
Cytogen Corporation Reports First Quarter 2007 Financial Results
5/10/2007
-
Cytogen Corporation to Release First-Quarter 2007 Financial Results and Host Conference Call on Wednesday May 9, 2007
5/4/2007
-
Preclinical Data on Cytogen Corporation's Technology to be Reported at the American Association for Cancer Research Annual Meeting
3/29/2007
-
New Clinical Data for Cytogen Corporation's QUADRAMET and PROSTASCINT to be Reported at Upcoming Major Medical Meetings
3/26/2007